Brusatol Inhibits Tumor Growth and Increases the Efficacy of Cabergoline against Pituitary Adenomas

Cabergoline (CAB) is the first choice for treatment of prolactinoma and the most common subtype of pituitary adenoma. However, drug resistance and lack of effectiveness in other pituitary tumor types remain clinical challenges to this treatment. Brusatol (BT) is known to inhibit cell growth and prom...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zerui, Xu, Yunqiu, Xu, Jiadong, Lu, Jianglong, Cai, Lin, Li, Qun, Wang, Chengde, Su, Zhipeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221873/
https://www.ncbi.nlm.nih.gov/pubmed/34221237
http://dx.doi.org/10.1155/2021/6696015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8221873/
https://www.ncbi.nlm.nih.gov/pubmed/34221237
http://dx.doi.org/10.1155/2021/6696015

Ejemplares similares